| Notice |
Alteogen Signs License Agreement with AstraZeneca for Subcutaneous Oncology Therapy Development
alteogen
|
2025.03.17
|
Votes 0
|
Views 799
|
alteogen |
2025.03.17 |
| Notice |
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hy
alteogen
|
2024.11.14
|
Votes 0
|
Views 1971
|
alteogen |
2024.11.14 |
| Notice |
Alteogen announces amendment to license agreement with MSD.
alteogen
|
2024.02.24
|
Votes 0
|
Views 4773
|
alteogen |
2024.02.24 |
| Notice |
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
alteogen
|
2023.09.06
|
Votes 0
|
Views 4576
|
alteogen |
2023.09.06 |
| Notice |
Hyaluronidase : A new way to be excluded from drug price negotiations under IRA
alteogen
|
2023.08.01
|
Votes 0
|
Views 4524
|
alteogen |
2023.08.01 |
| Notice |
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 6606
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
alteogen
|
2023.01.06
|
Votes 0
|
Views 4610
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 4296
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 4417
|
alteogen |
2023.01.06 |
| Notice |
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 4169
|
alteogen |
2023.01.06 |
| 19 |
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen
|
2018.07.04
|
Votes 0
|
Views 3132
|
alteogen |
2018.07.04 |
| 18 |
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen
|
2018.05.28
|
Votes 0
|
Views 3281
|
alteogen |
2018.05.28 |
| 17 |
23 Aug. 2017 Alteogen set to start phase I trial of ADC product in Korea
alteogen
|
2018.05.28
|
Votes 0
|
Views 2395
|
alteogen |
2018.05.28 |
| 16 |
26 APR 2017 Alteogen partners with Cristalia to develop long-acting growth hormone
alteogen
|
2018.05.28
|
Votes 0
|
Views 2439
|
alteogen |
2018.05.28 |
| 15 |
20 APR 2017 Alteogen to enter late-stage study of Herceptin biosimilar
alteogen
|
2018.05.28
|
Votes 0
|
Views 2160
|
alteogen |
2018.05.28 |
| 14 |
29 MAR 2017 Korean firm to transfer biosimilar tech to Chinese partner
alteogen
|
2018.05.28
|
Votes 0
|
Views 2170
|
alteogen |
2018.05.28 |
| 13 |
29 DEC 2016 Alteogen patents
alteogen
|
2018.05.28
|
Votes 0
|
Views 2170
|
alteogen |
2018.05.28 |
| 12 |
22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
alteogen
|
2018.05.28
|
Votes 0
|
Views 2286
|
alteogen |
2018.05.28 |
| 11 |
7 Oct 2016 Alteogen receives patent in Japan
alteogen
|
2018.05.28
|
Votes 0
|
Views 2161
|
alteogen |
2018.05.28 |
| 10 |
7 Mar 2016 Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulator
alteogen
|
2018.05.28
|
Votes 0
|
Views 1937
|
alteogen |
2018.05.28 |
